Maxim Group restated their buy rating on shares of Atossa Genetics (NASDAQ:ATOS) in a research report report published on Friday morning, AnalystRatings.com reports. The firm currently has a $8.00 price objective on the stock.
Separately, Ascendiant Capital Markets began coverage on Atossa Genetics in a report on Thursday. They issued a buy rating and a $7.00 price objective for the company.
Shares of NASDAQ ATOS opened at $2.44 on Friday. The stock’s 50-day simple moving average is $3.04 and its two-hundred day simple moving average is $2.53. Atossa Genetics has a twelve month low of $0.75 and a twelve month high of $5.08.
About Atossa Genetics
Atossa Genetics Inc a clinical-stage pharmaceutical company, focuses on the development and sale of novel therapeutics and delivery methods for the treatment of breast cancer and other breast conditions in the United States. The company is conducting a Phase 2 clinical study using microcatheters to deliver fulvestrant as a potential treatment of ductal carcinoma in situ and breast cancer; and a pharmaceutical program under development is Endoxifen, an active metabolite of tamoxifen, as well as treatment for breast density and other breast health conditions.
Receive News & Ratings for Atossa Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atossa Genetics and related companies with MarketBeat.com's FREE daily email newsletter.